Eric Ko to Head and Neck Neoplasms
This is a "connection" page, showing publications Eric Ko has written about Head and Neck Neoplasms.
Connection Strength
1.434
-
Ko EC, Hanna GJ. Immunotherapy for head and neck cancer: where do we go from here? Immunotherapy. 2023 12; 15(18):1497-1500.
Score: 0.796
-
Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen CT, Packer S, Kao J. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep. 2012 Feb; 27(2):467-74.
Score: 0.344
-
Carpenter TJ, Kann B, Buckstein MH, Ko EC, Bakst RL, Misiukiewicz KJ, Posner MR, Genden EM, Gupta V. Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2014 Nov; 123(11):791-7.
Score: 0.103
-
D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.
Score: 0.102
-
Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso J, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012 May; 27(5):1580-6.
Score: 0.088